This anti-human antibody is great for studying TLT-1 in humans and a potential diagnostic, prognostic, and therapeutic agent for clotting disorders, sepsis, thrombosis, cardiovascular disease (CVD), among other diseases with a TLT-1 component.
| Inventor | Institute |
|---|---|
| Anthony Valance Washington | University of Puerto Rico |
| Cat. #: | 161643 |
|---|---|
| Tool sub type: | Primary antibody |
| Cancer types: | Lung cancer |
| Research Fields: | Immunology |
| Application: | Flow cytometry, western blot, immunofluorescence, ELISA, and immunoprecipitation |
| Target: | Human TLT-1 Platelet Activator |
| Reactivity: | Human |
| Clone: | AB69 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Schmoker AM et al. J Proteomics. 215:103638. PMID: 31923473. |
| Product description: | Monoclonal a69 Antibody Targeting the Human TLT-1 Platelet Activator. This monoclonal antibody recognizes the extracellular fragment of the human TLT-1 (CDR3 loop), conserved in all three reported TLT-1 isoforms in platelets |
|---|---|
| Isotype: | IgG2b |
| Target background: | alpha-granules of platelets and megakaryocytes |
|---|
| Shipping conditions: | Dry ice |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.